ST1535

ST1535 is an adenosine A2A receptor antagonist. It is selective for adenosine A2A over A1 receptors (Kis = 2.3 and 107 nM, respectively, in radioligand binding assays). ST1535 inhibits agonist-induced production of cAMP in CHO cells expressing adenosine A2A receptors (IC50 = 353 nM). In vivo, ST1535 (10 and 20 mg/kg) reduces haloperidol-induced catalepsy in mice. It reduces the number of jaw tremors in a rat model of Parkinsonian jaw tremors induced by tacrine (Cay-70240). ST1535 (20 and 40 mg/kg) increases locomotor activity and reverses motor disabilities in a marmoset model of MPTP-induced Parkinson's disease.Formal Name: 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine. CAS Number: 496955-42-1. Molecular Formula: C12H16N8. Formula Weight: 272.3. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 5mg/mL, DMSO: 5mg/mL, DMSO:PBS (pH 7.2) (1:9): 0.1mg/mL. lambdamax: 233, 290 nm. SMILES: CCCCC1=NC(N)=C2C(N(C)C(N3N=CC=N3)=N2)=N1. InChi Code: InChI=1S/C12H16N8/c1-3-4-5-8-16-10(13)9-11(17-8)19(2)12(18-9)20-14-6-7-15-20/h6-7H,3-5H2,1-2H3,(H2,13,16,17). InChi Key: CYYQMAWUIRPCNW-UHFFFAOYSA-N.